Trial Profile
A 4-week randomized, double-blind, placebo controlled, parallel group, phase II study to assess the efficacy and safety of gefitinib tablets, 250 mg once daily (OD), in adult patients with moderate chronic obstructive pulmonary disease (COPD)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2016
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms GECO
- Sponsors AstraZeneca
- 02 Jun 2011 New trial record